CytoGam^® (cytomegalovirus immune globulin intravenous (human)) (CMV-IVIG) is an intravenous immune globulin enriched in antibodies against cytomegalovirus (CMV), and it is indicated for prophylaxis against CMV disease associated with transplantation In transplants of organs from CMV seropositive donors into CMV seronegative recipients, prophylactic CMV-IVIG should be considered in combination with ganciclovir.

CMV is the most common cause of infection occurring after any solid organ transplant, contributing significantly to morbidity and mortality in organ transplant recipients. CMV can cause severe pneumonia and other organ complications related to invasive disease which, if not successfully treated, can lead to organ failure. CMV has also been shown to cause increased bacterial and fungal infections, and has been associated with an increased risk of rejection of the transplanted organ.

CytoGam® is the only IVIG product indicated for the prevention of CMV post transplant.  Contact us to inquire about how CytoGam can help your patents today! 

In Canada, CytoGam is available through your hospital blood bank.  If your hospital blood bank does not have the product on hand or you are a medical professional at another medical facility contact Genesis Bio-Pharmaceuticals to determine how the product(s) can be obtained.